MX9706827A - Activacion de receptor por gas6. - Google Patents

Activacion de receptor por gas6.

Info

Publication number
MX9706827A
MX9706827A MX9706827A MX9706827A MX9706827A MX 9706827 A MX9706827 A MX 9706827A MX 9706827 A MX9706827 A MX 9706827A MX 9706827 A MX9706827 A MX 9706827A MX 9706827 A MX9706827 A MX 9706827A
Authority
MX
Mexico
Prior art keywords
gas6
cells
rse
polypeptide
mer receptor
Prior art date
Application number
MX9706827A
Other languages
English (en)
Inventor
Jian Chen
R Glenn Hammonds
Paul J Godowski
Melanie R Mark
Jennie P Mather
Ronghao Li
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/402,253 external-priority patent/US6211142B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX9706827A publication Critical patent/MX9706827A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Se ha identificado un activador de las proteínas receptoras Rse y Mer de tirosina cinasas. El activador es codificado por el gen específico de supresion de crecimiento 6 (gas6). En consecuencia, la invencion proporciona un método para activar el receptor de Rse o Mer utilizando el polipéptido gas6. Además, la invencion proporciona un método para mejorar la supervivencia, proliferacion y diferenciacion de células que tienen el receptor Rse o Mer incorporando en sus membranas celulares lo cual involucra a estas células con el polipéptido gas6. Los tipos de células los cuales pueden ser tratados de acuerdo con el método incluyen células de la glia tales como células de Schwann y células mononucleares. Se proporcionan adicionalmente equipos y artículos de fabricacion los cuales incluyen al polipéptido gas6. La invencion también se relaciona con variantes de gas6.
MX9706827A 1995-03-10 1996-03-05 Activacion de receptor por gas6. MX9706827A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/402,253 US6211142B1 (en) 1995-03-10 1995-03-10 Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US43886195A 1995-05-10 1995-05-10
PCT/US1996/003031 WO1996028548A1 (en) 1995-03-10 1996-03-05 Receptor activation by gas6

Publications (1)

Publication Number Publication Date
MX9706827A true MX9706827A (es) 1997-11-29

Family

ID=27017784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706827A MX9706827A (es) 1995-03-10 1996-03-05 Activacion de receptor por gas6.

Country Status (11)

Country Link
US (1) US6169070B1 (es)
EP (1) EP0815224B1 (es)
JP (1) JP3342873B2 (es)
AT (1) ATE271606T1 (es)
AU (1) AU712585B2 (es)
CA (1) CA2214629C (es)
DE (1) DE69632949T2 (es)
ES (1) ES2225874T3 (es)
IL (1) IL117425A0 (es)
MX (1) MX9706827A (es)
WO (1) WO1996028548A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999049894A1 (en) * 1998-04-01 1999-10-07 Genentech, Inc. Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
ES2569919T3 (es) * 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
MXPA01011845A (es) * 1999-05-19 2002-06-21 Lexigen Pharm Corp Expresion y exportacion de proteinas de interferon-alfa como proteinas de fusion fc.
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
HUP0202442A3 (en) * 1999-08-09 2005-01-28 Lexigen Pharmaceuticals Corp L Multiple cytokine-antibody complexes
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
US20030144237A1 (en) * 2000-04-13 2003-07-31 Peter Carmeliet Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
EP1199081A1 (en) * 2000-10-20 2002-04-24 Vlaams Interuniversitair Instituut voor Biotechnologie Use of inhibition of a growth arrest-specific gene (gas6) function or of a gas6 receptor for preventing and treating a thromboembolic disease
AU7172901A (en) * 2000-06-29 2002-01-14 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
RU2306320C9 (ru) * 2001-05-03 2008-01-27 Мерк Патент Гмбх Рекомбинантное опухолеспецифичное антитело (варианты) и его применение
GB2378899A (en) * 2001-08-25 2003-02-26 Thromb X N V Treatment of anemia
RU2312677C9 (ru) * 2001-12-04 2008-03-27 Мерк Патент Гмбх Иммуноцитокины с модулированной селективностью
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20040157774A1 (en) * 2002-09-24 2004-08-12 Jing Yang Epitope-tagged recombinant Growth Arrest Specific Gene 6 protein
WO2004108748A2 (en) * 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
DK1572748T3 (da) * 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
US20060183671A1 (en) * 2003-07-17 2006-08-17 Anne Angelillo-Scherrer Treatment of anemia
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
CN100467488C (zh) * 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US8420087B2 (en) * 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP4937132B2 (ja) * 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫原性の低下したｉｌ−７変種
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) * 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
WO2009062112A2 (en) * 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
EP2421896A1 (en) * 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
WO2012149018A1 (en) * 2011-04-25 2012-11-01 The Regents Of The University Of Colorado Mer tyrosine kinase inhibitors and methods of making and using the same
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2023212664A1 (en) * 2022-04-27 2023-11-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Synapse surgery tools and associated methods for neural circuit-specific synapse ablation and modification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585269A (en) * 1994-06-02 1996-12-17 The University Of North Carolina At Chapel Hill Isolated DNA encoding c-mer protooncogene
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells

Also Published As

Publication number Publication date
JPH10505507A (ja) 1998-06-02
EP0815224A1 (en) 1998-01-07
AU712585B2 (en) 1999-11-11
AU5183696A (en) 1996-10-02
US6169070B1 (en) 2001-01-02
JP3342873B2 (ja) 2002-11-11
CA2214629C (en) 2001-07-10
WO1996028548A1 (en) 1996-09-19
EP0815224B1 (en) 2004-07-21
DE69632949D1 (de) 2004-08-26
CA2214629A1 (en) 1996-09-19
DE69632949T2 (de) 2005-07-28
IL117425A0 (en) 1996-07-23
ES2225874T3 (es) 2005-03-16
ATE271606T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
MX9706827A (es) Activacion de receptor por gas6.
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
ATE140968T1 (de) Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert
ZA947825B (en) Stem cell proliferation factor.
MXPA99007026A (es) Metodo para proliferacion y diferenciacion de celulas hematopoieticas y mesenquimatosas.
ES8700320A1 (es) Metodo de obtencion del exprimido de una materia seleccionada que contiene renina.
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
EP0833912A4 (en) NEW TRANSFORMING GROWTH FACTOR TYPE CYTOKINE TGF-BETA
NZ510356A (en) Molecules designated LDCAM
CA2079454A1 (en) Steroid 5.alpha.-reductases
AU682140B2 (en) Multidrug resistance gene
ATE246251T1 (de) Verfahren zur herstellung von polypeptiden in surfaktinmutanten von bacillus zellen
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
ATE113982T1 (de) Verzweigungsenzym und dessen verwendung.
GB9825096D0 (en) Cells,culture methods and their uses
GB2322132B (en) Keratinocyte growth factor-2 products
WO2000036113A3 (en) Extending graft survival by heme oxygenase-i expression induced immunomodulation
EP2281892A3 (en) Methods for producing polypeptides in respiratory-deficient Trichoderma cells
GB9312315D0 (en) Leukocyte adhesion assay
IL154543A0 (en) The neurotrophic factor nnt-1
PL313257A1 (en) Novel tripeptides useful in treating immune system and central nervous system
AU8107094A (en) Endothelin-converting enzyme
DE59911877D1 (de) Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
NZ310563A (en) DNA encoding a porcine complement inhibitor
ATE326526T1 (de) Verfahren zur herstellung von neuronalem zellmaterial